These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 31831187)

  • 1. Current Strategies for the Management of Bleeding Associated with Direct Oral Anticoagulants and a Review of Investigational Reversal Agents.
    Kaide CG; Gulseth MP
    J Emerg Med; 2020 Feb; 58(2):217-233. PubMed ID: 31831187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idarucizumab and Factor Xa Reversal Agents: Role in Hospital Guidelines and Protocols.
    Huisman MV; Fanikos J
    Am J Med; 2016 Nov; 129(11S):S89-S96. PubMed ID: 27569673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of Newer Direct Oral Anticoagulant Drugs (DOACs).
    Hussain SS; Tyroch AH; Mukherjee D
    Cardiovasc Hematol Agents Med Chem; 2017; 14(2):76-81. PubMed ID: 27215215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How can we reverse bleeding in patients on direct oral anticoagulants?
    Crowther M; Cuker A
    Kardiol Pol; 2019; 77(1):3-11. PubMed ID: 30338501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols.
    Huisman MV; Fanikos J
    Am J Emerg Med; 2016 Nov; 34(11S):46-51. PubMed ID: 27697438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures.
    Levy JH
    Am J Med; 2016 Nov; 129(11S):S47-S53. PubMed ID: 27569675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal agents for use with direct and indirect anticoagulants.
    Smythe MA; Trujillo T; Fanikos J
    Am J Health Syst Pharm; 2016 May; 73(10 Suppl 2):S27-48. PubMed ID: 27147456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of direct oral anticoagulants.
    Almegren M
    Vasc Health Risk Manag; 2017; 13():287-292. PubMed ID: 28769570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal agents for non-vitamin K antagonist oral anticoagulants.
    Levy JH; Douketis J; Weitz JI
    Nat Rev Cardiol; 2018 May; 15(5):273-281. PubMed ID: 29345686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents.
    Ruff CT; Giugliano RP; Antman EM
    Circulation; 2016 Jul; 134(3):248-61. PubMed ID: 27436881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH.
    Levy JH; Shaw JR; Castellucci LA; Connors JM; Douketis J; Lindhoff-Last E; Rocca B; Samama CM; Siegal D; Weitz JI
    J Thromb Haemost; 2024 Oct; 22(10):2889-2899. PubMed ID: 39029742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discontinuation and management of direct-acting anticoagulants for emergency procedures.
    Levy JH
    Am J Emerg Med; 2016 Nov; 34(11S):14-18. PubMed ID: 27697442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antidotes for reversal of direct oral anticoagulants.
    Dobesh PP; Bhatt SH; Trujillo TC; Glaubius K
    Pharmacol Ther; 2019 Dec; 204():107405. PubMed ID: 31521696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal agents for direct oral anticoagulants: considerations for hospital physicians and intensivists.
    Desai NR; Cornutt D
    Hosp Pract (1995); 2019 Aug; 47(3):113-122. PubMed ID: 31317796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversing the Effect of Oral Anticoagulant Drugs: Established and Newer Options.
    Ansell JE
    Am J Cardiovasc Drugs; 2016 Jun; 16(3):163-70. PubMed ID: 26872887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical and clinical data for factor Xa and "universal" reversal agents.
    Milling TJ; Kaatz S
    Am J Emerg Med; 2016 Nov; 34(11S):39-45. PubMed ID: 27697443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [State of the art: Direct oral anticoagulants and transfusion].
    Martin AC; Godier A; Smadja DM; Mauge L; Fischer AM
    Transfus Clin Biol; 2017 Sep; 24(3):154-159. PubMed ID: 28673500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Latest advances in the reversal strategies for direct oral anticoagulants.
    Escal J; Lanoiselée J; Poenou G; Zufferey P; Laporte S; Mismetti P; Delavenne X
    Fundam Clin Pharmacol; 2024 Aug; 38(4):674-684. PubMed ID: 38350629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors: Andexanet Alfa (ANDEXXA).
    Rogers KC; Finks SW
    Am J Med; 2019 Jan; 132(1):38-41. PubMed ID: 30053385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring and reversal of direct oral anticoagulants.
    Cuker A; Siegal D
    Hematology Am Soc Hematol Educ Program; 2015; 2015():117-24. PubMed ID: 26637710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.